Cagrilintide is a long-acting amylin receptor agonist currently in active clinical development for obesity and type 2 diabetes, often studied in combination with GLP-1 agonists. As an RUO compound, it is used in research examining amylin receptor signalling, satiety regulation, and glucagon suppression pathways. Demand is growing rapidly among CROs focused on metabolic disease pharmacology. Purity ≥98%, supplied lyophilised. For research use only.

Why customers choose us — benefits and guarantees.

Delivery times, returns policy and related info.